In general, mitochondrial hexokinase II is a good target in anti-cancer strategies, since it is required for tumor initiation and maintenance in mouse models of K-Ras-driven lung cancer, as its ablation in conditional knockout mice inhibits tumor growth without side effects (Patra et al. 2013). Here, KRAS is linked to neoplasm.